BPC-157 and TB-500 appear together constantly in regenerative literature, yet they act through entirely separate pathways. Here is the distinction, and how to handle each.
BPC-157 is a 15-residue synthetic fragment derived from a gastric protein sequence. TB-500 is a 7-residue fragment of thymosin beta-4. They are grouped together by search behaviour, not by pharmacology.
| Compound | Length | Studied pathway | Solution stability |
|---|---|---|---|
| BPC-157 | 15 residues | Angiogenic and growth-factor signalling | Comparatively robust in solution |
| TB-500 | 7 residues | Actin sequestration and cell migration | Robust; short sequence, simple handling |
Why they are frequently studied in parallel
- The pathways are non-overlapping, so parallel arms do not confound one another.
- Both are short sequences with straightforward analytical profiles.
- Both tolerate standard lyophilised storage and bacteriostatic-water reconstitution.
Handling blends correctly
Pre-mixed blend vials save handling steps but cost analytical resolution. A blend certificate must report purity per component, not one combined figure — otherwise a low-purity component hides behind a high-purity one. Restore Labs reports blends component by component.
Regenerative peptide FAQ
Are BPC-157 and TB-500 the same class?
No. They are unrelated sequences acting on separate pathways; only their research context overlaps.
Should a blend or separate vials be ordered?
Separate vials give independent concentration control and cleaner per-component documentation. Blends are a convenience trade-off.
